Death

By 2035, Canada could have the most enviable healthcare system in the world if obesity is recognized as a chronic disease, predicts Obesity Canada

Retrieved on: 
Wednesday, March 27, 2024
Health, Conditional sentence, Cardiovascular disease, Conference, Obesity, Pressure, Notifiable disease, Hypertension, Diabetes, Accreditation, Research, Obesity Canada, Science, Death, Cancer, BMI, Pharmaceutical industry

The multiplication factor of obesity: Obesity is intricately linked with various chronic diseases, including cardiovascular diseases, diabetes, certain cancers, and joint problems, placing an immense burden on individual health and healthcare systems.

Key Points: 
  • The multiplication factor of obesity: Obesity is intricately linked with various chronic diseases, including cardiovascular diseases, diabetes, certain cancers, and joint problems, placing an immense burden on individual health and healthcare systems.
  • Obesity can be treated effectively; we know what to do: Canada is a global leader in obesity research and clinical expertise.
  • The Canadian Obesity Clinical Practice Guidelines are globally recognized as the gold standard and Canadian experts are highly regarded as thought leaders.
  • Revolutionizing our healthcare system: By officially recognizing obesity as a chronic disease and investing in evidence-based strategies, Canada (provincial and territorial health ministries) has the potential to lead the world in healthcare excellence within the next decade, predicts Obesity Canada.

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

Retrieved on: 
Wednesday, March 27, 2024
Research, Finkelstein, Arrhythmia, Stroke, Annual report, Certification, Myocardial infarction, BCDA, Partnership, Patient, The Study, Morph, Mortality, Form 10-K, Security (finance), Death, Heart transplantation, Quality of life, Doctor of Philosophy, Heart failure, Therapy, Heart, Safety, Data, Medicare, FDA, Helix, Arrest, Hospital, Pharmaceutical industry

The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights with call details below.

Key Points: 
  • The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights with call details below.
  • The Company anticipates completing follow-up in the trial and preparing this dataset on 115 randomized patients enrolled with a minimum of one-year follow-up for final lock in the fourth quarter of 2024.
  • BioCardia has had discussions on partnering its CardiAMP therapy for other clinical indications and continues to explore partnerships worldwide.
  • All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioCardia call.

PLI Treatise Addresses Income Tax Opportunities and Traps for Transfers After Death

Retrieved on: 
Wednesday, March 27, 2024
Code, Income tax, Trust, Death, Life insurance

A new treatise from PLI Press, Income Taxation of Property Acquired from a Decedent , is an essential resource for tax practitioners and others who advise on estate and income tax matters, covering planning opportunities and traps to consider before and after death.

Key Points: 
  • A new treatise from PLI Press, Income Taxation of Property Acquired from a Decedent , is an essential resource for tax practitioners and others who advise on estate and income tax matters, covering planning opportunities and traps to consider before and after death.
  • “With proper, informed planning, discrepancies under the Code can be cured, traps can be avoided, and traditional estate planning techniques combined with additional income tax planning can lead to favorable results for both estate and income tax,” says the treatise’s author, Matthew S. Beard.
  • Comprehensively addressing income tax issues related to transfers after death, the publication’s topics include the exclusion from gross income under I.R.C.
  • § 1014, the application of these rules to common trust and entity structures in estate planning, substantiation, and planning opportunities and potential traps for the unwary to consider before and after death.

Green Builder Media’s Virtual Sustainability Symposium Is Coming Up ... Reserve Your Spot!

Retrieved on: 
Wednesday, March 27, 2024
Physics, Climate change, RMI (energy organization), Growth, Steel, Symposium, ESG, Politics, Symposium (Plato), Hope, Death, Wind, Nature, Life, Carbon, Outline, Green Builder Media, Trane Technologies, Whirlpool Corporation, Progress, Hydrogen, Apathy, Economics, Renewable energy

The Symposium, which is free to all attendees, will be held virtually over two days from 12:00-3:00 pm ET each day.

Key Points: 
  • The Symposium, which is free to all attendees, will be held virtually over two days from 12:00-3:00 pm ET each day.
  • Green Builder Media's dynamic CEO, Sara Gutterman, unveils the hottest sustainability trends revolutionizing the landscape for building professionals, homeowners, and businesses.
  • (If you want to read more details about the symposium before registering, check out the webpage here. )
  • A heartfelt thank you to Trane Technologies and Whirlpool Corporation for their continued support of our annual Sustainability Symposium, as well as their comprehensive commitment to corporate sustainability.

Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID

Retrieved on: 
Wednesday, March 27, 2024
COVID, Type, COVID-19, Patient, Heart rate, Research, RVV, Death, Doctor of Philosophy, Trial of the century, Cough, CDC, Harvard University, Fever, Safety, Therapy, Disorder, FDA, Economics, Hospital, Pharmaceutical industry

Following the submission of the Type C meeting request package, the Company expects to hear from the FDA on a firm date for the meeting.

Key Points: 
  • Following the submission of the Type C meeting request package, the Company expects to hear from the FDA on a firm date for the meeting.
  • The CDC estimates that 7.5 percent of U.S. adults have long COVID symptoms1.
  • Currently, the Company is exploring the use of Bucillamine as a potential treatment for long COVID.
  • The Company is advancing the clinical development of Bucillamine by leveraging the published research and data from its previous Phase 3 clinical trial (the “Study”) and is finalizing the regulatory and clinical package that includes a proposed clinical study for long COVID to present to the FDA.

NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES

Retrieved on: 
Wednesday, March 27, 2024
WEE1, Netherlands Cancer Institute, Bernards, Cell, Professor, Malignancy, Neoplasm, Cancer, Death, Cancer Discovery (journal), Vaccine

PASADENA, CA, March 27, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, announced today publication of pre-clinical data in the online journal, Cancer Discovery, showing that its lead clinical compound, LB-100, can force cancer cells to give up their cancer-causing properties in a paper entitled “Paradoxical activation of oncogenic signaling as a cancer treatment strategy.” The finding opens a potentially new treatment strategy in addition to LIXTE’s current three clinical trials.

Key Points: 
  • The deliberate hyper-activation of cancer signals becomes lethal when combined with an inhibitor of the WEE1 kinase.
  • This well-tolerated combination proved to be highly effective in killing colon cancer cells in animal models of cancer and in cell culture.
  • Resistance to LB-100 therapy, however, has been shown to be associated with cancer cells becoming less malignant.
  • Although cancer-causing signals force cancer cells to become more cancerous, the hyper-activation of these signals by LB-100 forces cancer cells to suppress these signals and thus become less cancerous.

Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

Retrieved on: 
Wednesday, March 27, 2024
Infection, Risk, COVID-19, Patient, Fast Track, Viral, Data monitoring committee, Death, Doctor of Philosophy, Safety, DSMB, Immunodeficiency, Atea, Food, Hospital, Pharmaceutical industry

BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that the company has completed enrollment of the global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir, an oral nucleotide polymerase inhibitor, or placebo for the treatment of COVID-19. Over 2,200 patients were randomized into the supportive care monotherapy cohort and less than 80 patients were randomized into the combination cohort. The primary endpoint of the trial is all-cause hospitalization or death through Day 29 post-treatment in the bemnifosbuvir supportive care monotherapy cohort of high-risk patients. Secondary endpoints include other measurements of patient outcomes through Day 60 post-treatment.

Key Points: 
  • Over 2,200 patients were randomized into the supportive care monotherapy cohort and less than 80 patients were randomized into the combination cohort.
  • The primary endpoint of the trial is all-cause hospitalization or death through Day 29 post-treatment in the bemnifosbuvir supportive care monotherapy cohort of high-risk patients.
  • Secondary endpoints include other measurements of patient outcomes through Day 60 post-treatment.
  • “COVID-19 continues to be a threat, leaving the most vulnerable at risk for severe outcomes from infection.

Evolv Technologies Holdings, Inc investors: Please contact the Portnoy Law Firm to recover your losses; May 24, 2024 deadline

Retrieved on: 
Tuesday, March 26, 2024
Safety, MAX, Risk, Boeing, Death, Airline

LOS ANGELES, March 26, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Evolv Technologies Holdings, Inc. f/k/a NewHold Investment Corp. (NASDAQ: EVLV) investors that a lawsuit was filed on behalf of investors that purchased Evolv securities between June 28, 2021 and March 13, 2024, inclusive (the “Class Period”).

Key Points: 
  • Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 310-692-8883 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • Boeing, a leading aerospace company based in Arlington, Virginia, faced significant challenges related to its 737 MAX aircraft.
  • The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing.

HeartFlow Initiates DECIDE Registry to Evaluate Utility of HeartFlow AI-Enabled Plaque Analysis for Patients with Suspected Coronary Artery Disease

Retrieved on: 
Tuesday, March 26, 2024
Nuclear, Education, Coronary artery disease, Disease, Safety, Partnership, Physiology, Anatomy, Patient, Journal, Biomarker, AI, Death, Plaque, Society, CAD, CCTA, Charleston Area Medical Center, MACE, Cone Health, Collection, FDA, Physician, IVUS, Hospital

The registry will collect multi-site, real-world information on how the Plaque Analysis product provides enhanced patient insights, empowering physicians and helping to inform their medical management decisions for patients with suspected coronary artery disease (CAD).

Key Points: 
  • The registry will collect multi-site, real-world information on how the Plaque Analysis product provides enhanced patient insights, empowering physicians and helping to inform their medical management decisions for patients with suspected coronary artery disease (CAD).
  • The DECODE study showed that clinicians using the HeartFlow Plaque Analysis changed their management decisions for 66% of patients compared to CCTA alone across various patient presentations and disease stages.
  • “We believe real-world prospective data from the new DECIDE Registry will empower clinicians with enhanced patient insights leveraging HeartFlow Plaque Analysis to improve patient outcomes.
  • The primary endpoint for this registry will highlight change in medical management after HeartFlow Plaque Analysis compared to after CCTA alone.

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

Retrieved on: 
Tuesday, March 26, 2024
Corporation, Toxicity, SLS, Survival, AML, Committee, Biomarker, GPS, Death, BIW, Enrollment, MD, Date, Trial of the century, Doctor of Science, Safety, IDMC, Pharmaceutical industry

The Company will host a webinar to discuss the data and the REGAL update today at 8:15 am ET.

Key Points: 
  • The Company will host a webinar to discuss the data and the REGAL update today at 8:15 am ET.
  • “We are extremely grateful to the patients, their families, and investigators who have helped us achieve this significant milestone.
  • Additionally, we are pleased to share that the Steering Committee has reviewed the study as of the March 1, 2024, cutoff date.
  • Dr. Stergiou continued: “We are extremely excited to share positive topline data from the Phase 2a trial of SLS009 in AML patients resistant to venetoclax combination therapies.